By Colin Kellaher

Merck & Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its Vaxneuvance 15-valent pneumococcal vaccine in adults.

The Kenilworth, N.J., drugmaker said the recommendation covers Vaxneuvance for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.

The European Commission, which generally follows the CHMP's advice, will now review the recommendations, with decisions expected by the end of the year.

The U.S. Food and Drug Administration earlier this year approved Vaxneuvance for adults.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 15, 2021 08:13 ET (12:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Merck.
Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Merck.